Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 1:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 17:30:28
Basilea Pharm (BSLN.S, Swiss Exchange)
Závěr k 28.3.2024 Změna (%) Změna (CHF) Objem obchodů (CHF)
37,65 -0,26 -0,10 845 223
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiBasilea Pharmaceutica AG Allschwil
TickerBSLN
Kmenové akcie:Ordinary Shares
RICBSLN.S
ISINCH0011432447
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 147
Akcie v oběhu k 02.02.2024 11 981 636
MěnaCHF
Kontaktní informace
UliceHegenheimermattweg 167b
MěstoALLSCHWIL
PSČ4123
ZeměSwitzerland
Kontatní osobaPeer Schroeder
Funkce kontaktní osobyHead of Corporate Communications, Investor Relations
Telefon41 616 061 111
Fax41616061112
Kontatní telefon41 616 061 102

Business Summary: Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Basilea Pharmaceutica AG Allschwil revenues increased 7% to SF157.6M. Net income decreased 14% to SF10.5M. Revenues reflect Republic of Ireland segment increase of 66% to SF68.7M, Uruguay (Country) segment increase of 38% to SF10.2M. Net income was offset by Research & development expenses, net - B increase of 8% to SF77.7M (expense), Selling.
Odvětvová klasifikace
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICCommercial Physical Research
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Member of the Management CommitteeDavid Veitch5919.04.201801.09.2014
Member of the Management Committee, Chief Financial OfficerAdesh Kaul4910.04.201910.04.2019
Member of the Management Committee, Chief Technology OfficerGerrit Hauck5901.05.201801.05.2018
Member of the Management Committee, Chief Scientific OfficerLaurenz Kellenberger5727.01.200927.01.2009
General Counsel, Corporate SecretaryDamian Heller5801.01.2017
Head of Global Quality ManagementPeter Bielmeier57
Head of Global Human ResourcesUrsula Eberhardt6201.01.2017
Member of the Management Committee, Chief Medical OfficerMarc Engelhardt6001.01.201801.01.2018